This photo taken on March 31, 2025 shows the exhibition booth of Invest in China at Hannover Messe 2025 in Hannover, Germany.

HANNOVER, Germany, April 4 (Xinhua) -- Jochen Koeckler, Chairman of the Managing Board of Deutsche Messe AG, the organizer of Germany's Hannover Messe, said that Chinese products and solutions are ...

Investing.com -- Barclays has released its updated list of high-conviction European stock ideas for the second quarter, featuring three Overweight and three Underweight-rated names. Among the ...

Investing.com -- Barclays (LON: BARC) has released its updated list of high-conviction European stock ideas for the second quarter, featuring three Overweight and three Underweight-rated names. Among ...

Among approximately 1,000 companies represented this year, China is the second-largest exhibitor group after the host country Germany. Jochen Koeckler, Chairman of the Managing Board of Deutsche Messe ...

Amid the global wave of digital transformation in the healthcare industry, China's market is evolving from a "primary sales hub" to a "primary innovation hub." Recently, Hong Chow, Executive Vice ...

Merck (NYSE:MRK) is doubling down on China's biotech boomthis time with a $2 billion licensing deal for a potential blockbuster heart drug from Jiangsu Hengrui Pharmaceuticals. The deal gives ...

By Sriparna Roy (Reuters) -Merck has signed a licensing agreement for a heart disease drug with Jiangsu Hengrui Pharmaceuticals worth up to $2 billion, the latest in a series of deals U.S ...

Merck has signed a licensing agreement for a heart disease drug with Jiangsu Hengrui Pharmaceuticals worth up to $2 billion, the latest in a series of deals U.S. drugmakers have recently signed with ...

the latest in a series of deals U.S. drugmakers have recently signed with China-based firms. Large drugmakers including Merck and Eli Lilly (LLY.N), opens new tab have turned to Chinese biotechs ...

This year's two sessions is a reconfirmation of the confidence that Merck has in China because the Chinese government has set the economic growth target at 5 percent, focusing more on innovation ...

Merck (NYSE:MRK) is doubling down on China's biotech boomthis time with a $2 billion licensing deal for a potential blockbuster heart drug from Jiangsu Hengrui Pharmaceuticals. The deal gives Merck ...